title: Attenuated oncolytic measles virus strains as cancer therapeutics.
abstract: Attenuated measles virus vaccine strains have emerged as a promising oncolytic vector platform, having shown significant anti-tumor activity against a broad range of malignant neoplasms. Measles virus strains derived from the attenuated Edmonston-B (MV-Edm) vaccine lineage have been shown to selectively infect, replicate in and lyse cancer cells while causing minimal cytopathic effect on normal tissues. This review summarizes the preclinical data that led to the rapid clinical translation of oncolytic measles vaccine strains and provides an overview of early clinical data using this oncolytic platform. Furthermore, novel approaches currently under development to further enhance the oncolytic efficacy of MV-Edm strains, including strategies to circumvent immunity or modulate immune system responses, combinatorial approaches with standard treatment modalities, virus retargeting as well as strategies for in vivo monitoring of viral replication are discussed.
authors: Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors: P
authors: P
authors: Msaouel
authors: I D
authors: ID
authors: Iankov
authors: A
authors: A
authors: Dispenzieri
authors: E
authors: E
authors: Galanis
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008458:Measles Vaccine / Q000494:pharmacology* / Q000627:therapeutic use; D008459:Measles virus / Q000276:immunology / Q000502:physiology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology*; D014613:Vaccines, Attenuated / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D008458:Measles Vaccine; D014613:Vaccines, Attenuated